Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A Southwest Oncology Group Trial S0111

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8724-8729

  Hussain, Maha ^a   Tangen, Catherine M ^a   Lara Jr , Primo N ^a   Vaishampayan, Ulka N ^a   Petrylak, Daniel P ^a   Colevas, A Dimitrios ^a   Sakr, Wael A ^a   Crawford, E David ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPOTHILONE DERIVATIVE; ESTRAMUSTINE; FAMOTIDINE; IXABEPILONE; NIZATIDINE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; WARFARIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FOLLOW UP; HEMATOLOGIC DISEASE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HYPERSENSITIVITY; INFECTION; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; SKIN TOXICITY; SOFT TISSUE METASTASIS; STATISTICAL ANALYSIS; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; BLOOD; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG RESISTANCE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SOFT TISSUE TUMOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 33644843604     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.4448     Document Type: Article

References (19)

1. Hudes G, Einhorn L, Ross E, et al: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17:3160-3166, 1999
2. Picus J, Schultz M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results. Semin Oncol 26:14-18, 1999
3. Trivedi C, Redman B, Flaherty LE, et al: Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89:431-436, 2000
4. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004
5. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
6. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
7. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 272:2534-2541, 1997
8. Goodin S, Kane MP, Rubin EH: Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22:2015-2025, 2004
9. Lee FY, Borzilleri R, Fairchild CR, et al: BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437, 2001
10. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
11. Pienta KJ, Fisher EI, Eisenberger MA, et al: A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407). Prostate 46:257-261, 2001
12. Klein CE, Tangen CM, Braun TJ, et al: SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer-A Southwest Oncology Group study. Prostate 52:264-268, 2002
13. Galsky MD, Small EJ, Oh WK, et al: Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446, 2005
14. Thomas E, Tabernero J, Fornier M, et al: A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 22:8, 2003 (abstr 30)
15. Roche EE, Cure H, Bunnell C, et al: A phase II study of epothilone analog BMS-247550 in patients (pats) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:18, 2003 (abstr 69)
16. Abraham J, Agrawal M, Bakke S, et al: Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 21:1866-1873, 2003
17. Low J, Wedam S, Lee J, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005
18. Vansteenkiste J, Breton J, Sandler A, et al: A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLS) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22:626, 2003 (abstr 2519)
19. Rosenberg J, Kelly WK, Michaelson M, et al: A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 23:394s, 2005 (abstr 4566)